Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
Guggenhime surrendered shares to cover tax withholding on vesting RSUs, retaining about 164,000 shares valued at $10.12 million.
Overview
President and CFO Andrew Guggenhime reported the disposition of 2,705 shares of Vaxcyte, Inc. (NASDAQ:PCVX), according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($61.18); post-transaction value based on the September 2 market close ($61.58).
Details
Vaxcyte, Inc. is a clinical-stage biotechnology enterprise headquartered in San Carlos with 507 employees, focused on developing next-generation protein-based vaccines addressing significant gaps in infectious disease prevention. The company's strategic approach leverages advanced conjugate vaccine technology to create multi-valent formulations with enhanced immunogenicity and broader pathogen coverage compared to existing therapeutic options. With a market capitalization of $9.0 billion and a one-year share price appreciation of 95.12%, Vaxcyte represents investor confidence in its clinical pipeline and the substantial market opportunity within the global vaccine sector.
Source
Originally published at www.fool.com.
Related Articles
- I have two sons. Should I allow one son to build a $400,000 house on my property? I’m not permitted to subdivide the land.
- SpaceX is a buy as the rocket company can solve one major bottleneck, says Pivotal Research
- Stocks making the biggest moves premarket: Peloton Interactive, Roivant Sciences, Boston Scientific & more